Drug Database
Back to search

Czechia· CZ-0500940

LUMINITY

A perflutren, phospholipid-mikrosphären product containing perflutren gas in microspheres, registered in Czechia by Lantheus EU Limited, Shannon. The same ATC class is registered in 9 of our 19 countries.

ATC V08DA04

Checked against SÚKL (Czech Republic) on

Informational only — not a medical device.

SOURCE REGISTER · CZSÚKL (Czech Republic)normalisedLUMINITYATCV08DA04REGISTER NO.CZ-0500940PACKS LISTED0CHECKEDSeptember 28, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about perflutren gas in microspheresAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Perflutren, phospholipid-mikrosphären is registered in 9 of 19 countries.

Countries holding a registration under ATC V08DA04 (perflutren, phospholipid-mikrosphären), each read from that country’s own register.

  • This record: Czechia, from SÚKL (Czech Republic)
  • 5 of them publish a price we can compare per daily dose
Search perflutren, phospholipid-mikrosphären products by name

Perflutren, phospholipid-mikrosphären · ATC V08DA04

9 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

SÚKL (Czech Republic)
Active substance
PERFLUTREN GAS IN MICROSPHERES
Manufacturer
Lantheus EU Limited, Shannon
Country
Czechia (CZ)
ATC code
V08DA04
ATC class
Perflutren, Phospholipid-Mikrosphären
Reimbursed
Not published by this register
Source register
SÚKL (Czech Republic)
Last checked
September 28, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

159 interactions on record for perflutren, phospholipid-mikrosphären.

Graded by severity as the source publishes them — 36 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check perflutren, phospholipid-mikrosphären against other medicinesHow interaction checks work

Perflutren, phospholipid-mikrosphären · interactions on record

159 records

  • 36 severe
  • 121 moderate
  • 2 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • PapaverinC04AX38severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Perflutren, phospholipid-mikrosphären in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All perflutren, phospholipid-mikrosphären products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • United Kingdom (Northern Ireland) · Optison
  • Iceland · Optison
  • Liechtenstein · Optison
  • Norway · Optison

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/5946ce23-a064-4b0f-a41a-a3ec5a96c0fc
GET /v1/drugs/5946ce23-a064-4b0f-a41a-a3ec5a96c0fc?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "INJ/INF GAQ DIS",
  "source": "sukl",
  "strength": "150MCL/ML",
  "pack_size": "1X1,5ML",
  "substance": "PERFLUTREN GAS IN MICROSPHERES",
  "cz_kod_sukl": "0500940",
  "product_type": "CH",
  "substance_codes": "15555",
  "registration_state": "R",
  "registration_number": "EU/1/06/361/002"
}
API referenceMCP serverPlans

See everything about perflutren, phospholipid-mikrosphären.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console